Takara Biomedical Technology

Takara Bio is a global biotechnology leader headquartered in Japan that operates across three core segments: bioindustry, gene therapy, and CDMO services. The company is a pioneer in genetic engineering, having conducted the first gene therapy clinical trials in Japan and developed the widely utilized RetroNectin reagent for cell transduction. Its therapeutic pipeline is focused on oncology, featuring advanced programs such as TBI-1301, a siTCR therapy currently in Phase 3 for synovial sarcoma. Beyond drug development, Takara Bio provides extensive contract development and manufacturing services for viral vectors, mRNA, and cell-based therapies through its state-of-the-art Center for Gene and Cell Processing. The company also maintains a dominant position in the life sciences tools market, offering a comprehensive range of PCR reagents, enzymes, and scientific instruments.